

Attention: Donia Alwan
Associate Counsel
Medicines Patent Pool
Rue de Varembe 7
1202 Geneva Switzerland
Tel +41 22 533 50 50
office@medicinespatentpool.org
Date: 28 March 2025
Sent via email

Re: Notice of Breach - MPP/Desano - Desano Reply

Dear Sir/Madam,

The Medicines Patent Pool (MPP) has, since its inception, played a revolutionary role in the global healthcare landscape. By facilitating the sharing of pharmaceutical patents, MPP has broken down barriers in the industry, enabling a more rapid response to public health challenges. This not only accelerates medical innovation but also makes life-saving medications more accessible to those in need around the world.

Through MPP's facilitation, we signed sub-licensing agreements with Gilead in 2015, 2017 and 2019, securing licenses for a range of Gilead products.

Thanks to MPP's remarkable efforts, our company has been able to reach new heights. With MPP's support, we've forged connections with leading pharmaceutical innovators. As a result, the products we manufacture have extended their reach to patients in numerous low-and-middle-income countries, significantly improving their quality of life and well-being.

We're acutely aware of MPP's overarching mission to enhance global access to essential medicines. Guided by this very principle, we aspire to make our high-quality, affordable medications available to a broader patient population, including those in China and regions beyond the scope of the existing licensing agreement. To ensure that our initiatives to expand medication accessibility do not run afoul of the current agreements, we have to decide to terminate the aforesaid series of agreements with Gilead. After comprehensive consideration and thorough internal review, we believe this step better fulfills our shared commitment to improving global healthcare access. This letter serves as the formal termination notice in accordance with Clause 10.4 of the relevant agreements.

We want to make it abundantly clear that this decision in no way diminishes our respect for MPP's outstanding work. Your organization's performance has consistently set a high standard, and we remain sincerely grateful for the support and assistance provided over the years. We are fully committed to maintaining strong communication and actively cooperating with MPP on the other existing agreements.

Looking ahead, we are eager to explore more opportunities for collaboration mediated through MPP, including those involving Gilead. We believe that with MPP's continued leadership, we can further enhance global healthcare accessibility and drive positive change in the pharma industry.

Yours faithfully,



Li Jingpeng
Head, Legal
Shanghai Desano Pharmaceuticals Investment Co., Ltd.